Stockscreener 앱 받기
7.64
2.55%
-0.20
전일 마감가:
$7.84
열려 있는:
$7.82
하루 거래량:
880.31K
Relative Volume:
0.61
시가총액:
$681.04M
수익:
$380.79M
순이익/손실:
$49.27M
주가수익비율:
10.91
EPS:
0.7
순현금흐름:
$10.68M
1주 성능:
-0.97%
1개월 성능:
+9.46%
6개월 성능:
+101.05%
1년 성능:
+324.44%
1일 변동 폭
$7.48
$7.85
1주일 범위
$7.48
$8.30
52주 변동 폭
$1.7748
$8.72
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
명칭
Amylyx Pharmaceuticals Inc
전화
617-683-0917
주소
43 THORNDIKE STREET, CAMBRIDGE
AMLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
7.64 | 730.07M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Guggenheim | Buy |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-05-30 | 개시 | TD Cowen | Buy |
| 2025-04-07 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-11-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-03-18 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-11 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-07-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-01-05 | 개시 | BofA Securities | Buy |
| 2022-05-25 | 개시 | Citigroup | Buy |
| 2022-04-01 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
Amylyx Pharmaceuticals Inc 주식(AMLX)의 최신 뉴스
Amylyx Pharmaceuticals Advances ALS Treatment with AMX0114 Clinical Trial - MSN
Amylyx anticipates Avexitide Phase III data in H1 2026 while expanding rare disease pipeline - MSN
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2025 Earnings Call Transcript - Insider Monkey
Promising Market Potential and Financial Outlook for Amylyx Pharmaceuticals Inc. Driven by Avexitide’s Advancements - TipRanks
Amylyx Pharmaceuticals Q2 2025 Earnings Preview - MSN
Amylyx Pharmaceuticals: Progress in Trials and Financials - TipRanks
Amylyx Pharmaceuticals: Strategic Progress in Neurodegenerative Therapies and the Path to Long-Term Value - AInvest
Amylyx in 2026: A High-Risk, High-Reward Biotech Catalyst Play - AInvest
Progressive Supranuclear Palsy Market on Upward Trajectory During the Forecast Period (2025-2034) with Emerging Immunotherapies | DelveInsight - Yahoo Finance
Amylyx Pharmaceuticals' Q2 2025: Key Contradictions in PBH Patient Estimates, Trial Analysis, and Market Opportunities - AInvest
Amylyx Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Amylyx Pharmaceuticals’ Phase 3 Study on Avexitide: A Potential Game-Changer for Post-Bariatric Hypoglycemia - TipRanks
Promising Future for Amylyx Pharmaceuticals: Buy Rating Backed by Avexitide’s Market Potential - TipRanks
Amylyx (AMLX) Q2 Net Loss Narrows 43% - Nasdaq
Transcript : Amylyx Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results - BioSpace
Amylyx Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Amylyx Pharmaceuticals: A Biotech Undervalued by Momentum and Milestones - AInvest
Amylyx Pharmaceuticals Advances Avexitide Study for Post-Bariatric Hypoglycemia - TipRanks
Amylyx Pharmaceuticals’ ALS Study: A Potential Game-Changer for Investors - TipRanks
Amylyx Pharmaceuticals Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
After strategic reset, Amylyx downsizes, moves Cambridge HQ - The Business Journals
How volatile is Amylyx Pharmaceuticals Inc. stock compared to the marketAchieve exceptional returns with expert guidance - Jammu Links News
What is the dividend policy of Amylyx Pharmaceuticals Inc. stockMaximize gains with proven stock analysis - Jammu Links News
What are analysts’ price targets for Amylyx Pharmaceuticals Inc. in the next 12 monthsSkyrocketing profit margins - Jammu Links News
What are the latest earnings results for Amylyx Pharmaceuticals Inc.Build wealth with long-term growth strategies - Jammu Links News
What analysts say about Amylyx Pharmaceuticals Inc. stockBuild a portfolio that delivers consistent profits - Jammu Links News
Should I hold or sell Amylyx Pharmaceuticals Inc. stock in 2025Fastest return on investment - Jammu Links News
What makes Amylyx Pharmaceuticals Inc. stock price move sharplyBuild wealth faster with consistent investment plans - Jammu Links News
What are Amylyx Pharmaceuticals Inc. company’s key revenue driversBreakthrough wealth creation - Jammu Links News
What catalysts could drive Amylyx Pharmaceuticals Inc. stock higher in 2025Discover high-impact stocks for growth - Jammu Links News
Amylyx Pharmaceuticals Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - Jammu Links News
What institutional investors are buying Amylyx Pharmaceuticals Inc. stockMaximize your gains with expert trading tips - Jammu Links News
When is Amylyx Pharmaceuticals Inc. stock expected to show significant growthUnlock exclusive stock market forecasts - Jammu Links News
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX): Is Breakeven Near? - 富途牛牛
How many analysts rate Amylyx Pharmaceuticals Inc. as a “Buy”Unlock expert insights for smarter investing - Jammu Links News
Does Amylyx Pharmaceuticals Inc. stock perform well during market downturnsTransform your portfolio with high-yield stocks - Jammu Links News
Is it the right time to buy Amylyx Pharmaceuticals Inc. stockTriple-digit return opportunities - Jammu Links News
In Rare Move, FDA Panel Gives Support to Controversial ALS Drug in Second Review - Physician's Weekly
What is the risk reward ratio of investing in Amylyx Pharmaceuticals Inc. stockChart Pattern Updates For Fast Growth - Jammu Links News
Why Amylyx Pharmaceuticals Inc. stock attracts strong analyst attentionTrend Reversal Signal Prediction Plan - beatles.ru
Amylyx Pharmaceuticals Inc. Rebound Backed by Sentiment ShiftVerified Signal From Chart Patterns Detected - metal.it
Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 - BioSpace
Amylyx Pharmaceuticals Announces Q2 2025 Earnings Call: Here's How to Join the Discussion - Stock Titan
Can trapped investors hope for a rebound in Amylyx Pharmaceuticals Inc.Step-by-Step Trade Signal Implementation Guide Ready - metal.it
Amylyx Pharmaceuticals Inc (AMLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):